Nkarta(NKTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NKTX Nkarta

Trading 07-08 10:18:31 EDT

3.42

+0.04

+1.18%

High3.48	Low3.25	Vol106.38K
Open3.30	D1 Closing3.38	Amplitude6.65%
Mkt Cap244.69M	Tradable Cap206.72M	Total Shares71.55M
T/O361.62K	T/O Rate0.18%	Tradable Shares60.44M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NKTX","market":"US","secType":"STK","nameCN":"Nkarta","latestPrice":3.42,"timestamp":1783520310869,"preClose":3.38,"halted":0,"volume":106376,"delay":0,"changeRate":0.011834319526627229,"floatShares":60443200,"shares":71545358,"eps":-1.34905,"marketStatus":"Trading","change":0.04,"latestTime":"07-08 10:18:31 EDT","open":3.3,"high":3.475,"low":3.2501,"amount":361620.584644,"amplitude":0.066538,"askPrice":3.42,"askSize":149,"bidPrice":3.41,"bidSize":338,"shortable":3,"etf":0,"ttmEps":-1.34905,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1783540800000},"marketStatusCode":2,"adr":0,"listingDate":1594353600000,"exchange":"NASDAQ","adjPreClose":3.38,"preHourTrading":{"tag":"盘前","latestPrice":3.3066,"preClose":3.38,"latestTime":"08:39 EDT","volume":4082,"amount":13543.616774999999,"timestamp":1783514364178,"change":-0.0734,"changeRate":-0.021716,"amplitude":0.014763},"postHourTrading":{"tag":"盘后","latestPrice":3.32,"preClose":3.38,"latestTime":"19:57 EDT","volume":4271,"amount":14236.0453,"timestamp":1783468665129,"change":-0.06,"changeRate":-0.017751,"amplitude":0.044024},"volumeRatio":0.889775,"impliedVol":1.5381,"impliedVolPercentile":0.9602},"requestUrl":"/m/hq/s/NKTX","defaultTab":"news","newsList":[{"id":"2646574973","title":"Nkarta Joins H.C. Wainwright Cell Therapy Virtual Conference Fireside Chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2646574973","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646574973?lang=en_us&edition=fundamental","pubTime":"2026-06-26 20:45","pubTimestamp":1782477913,"startTime":"0","endTime":"0","summary":"Nkarta joins H.C. Wainwright Cell Therapy Virtual Conference fireside chatNkarta will participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on June 30.President Nadir Mahmood i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260626:nNDL7JQWb4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","IE00BN0W2T93.GBP","BK4585","IE00B64PRP62.GBP","LU2095319765.USD","BK4505","IE00BGHQF748.EUR","BK4139","BK4112","IE00BKPKM429.USD","IE00BN0W2V16.EUR","LU2210150020.SGD","BK4588","NKTX","SG9999014039.USD","LU2210149790.SGD","IE00B3QW5Z07.USD","IE00BN0W2W23.USD","SG9999014021.USD","SG9999014013.SGD","LU0314104364.USD","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645283589","title":"Nkarta initiated with a Buy at TD Cowen","url":"https://stock-news.laohu8.com/highlight/detail?id=2645283589","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645283589?lang=en_us&edition=fundamental","pubTime":"2026-06-23 19:33","pubTimestamp":1782214397,"startTime":"0","endTime":"0","summary":"TD Cowen initiated coverage of Nkarta (NKTX) with a Buy rating and no price target Nkarta is focused on the development of engineered natural kille...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nkarta-initiated-with-a-buy-at-td-cowen-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nkarta-initiated-with-a-buy-at-td-cowen-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4207","COWN","NKTX","BK4585","TD","BK4127","BK4139","BK4505","BK4566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645887248","title":"TD Cowen Initiates Nkarta at Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2645887248","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645887248?lang=en_us&edition=fundamental","pubTime":"2026-06-23 18:05","pubTimestamp":1782209157,"startTime":"0","endTime":"0","summary":"Nkarta (NKTX) has an average rating of buy and mean price target of $11.33, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and re","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK4585","BK4566","BK4127","COWN","NKTX","TD","BK4207","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645887487","title":"Phil Nadeau Reiterates Buy on Nkarta, Citing Differentiated NK Cell Platform and CD19 CAR NK Therapy as Key Long-Term Value Drivers","url":"https://stock-news.laohu8.com/highlight/detail?id=2645887487","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645887487?lang=en_us&edition=fundamental","pubTime":"2026-06-23 17:55","pubTimestamp":1782208524,"startTime":"0","endTime":"0","summary":"Nkarta (NKTX) has received a new Buy rating, initiated by TD Cowen analyst, Phil Nadeau. Phil Nadeau has given his Buy rating due to a combination ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/phil-nadeau-reiterates-buy-on-nkarta-citing-differentiated-nk-cell-platform-and-cd19-car-nk-therapy-as-key-long-term-value-drivers-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/phil-nadeau-reiterates-buy-on-nkarta-citing-differentiated-nk-cell-platform-and-cd19-car-nk-therapy-as-key-long-term-value-drivers-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CAR","NKTX","BK4139","BK4230","BK4505","BK4022"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645882416","title":"Nkarta Inc : TD Cowen Initiates Coverage With Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2645882416","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645882416?lang=en_us&edition=fundamental","pubTime":"2026-06-23 17:45","pubTimestamp":1782207949,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nFWN42V0JP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NKTX","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645075685","title":"Analysts Offer Insights on Healthcare Companies: Achieve Life Sciences (ACHV) and Nkarta (NKTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2645075685","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645075685?lang=en_us&edition=fundamental","pubTime":"2026-06-22 23:00","pubTimestamp":1782140419,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Achieve Life Sciences (ACHV) and Nkarta (NKTX) with ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-achieve-life-sciences-achv-and-nkarta-nktx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-achieve-life-sciences-achv-and-nkarta-nktx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","LU0128526141.USD","NKTX","XBI","BK4505","ACHV","LU0029874061.USD","BK4137","BK4139","XLV","BK4585","BK4581","BK4588","HCSG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642237485","title":"Nkarta Shareholders Back Directors, Auditor and Annual Say-on-Pay","url":"https://stock-news.laohu8.com/highlight/detail?id=2642237485","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642237485?lang=en_us&edition=fundamental","pubTime":"2026-06-12 06:25","pubTimestamp":1781216720,"startTime":"0","endTime":"0","summary":"The latest update is out from Nkarta ( ($NKTX) ). At its 2026 annual meeting of stockholders held on June 10, 2026, Nkarta, Inc. shareholders elect...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nkarta-shareholders-back-directors-auditor-and-annual-say-on-pay?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/nkarta-shareholders-back-directors-auditor-and-annual-say-on-pay?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4505","NKTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642234050","title":"Nkarta shareholders elect directors at annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2642234050","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642234050?lang=en_us&edition=fundamental","pubTime":"2026-06-12 04:59","pubTimestamp":1781211581,"startTime":"0","endTime":"0","summary":"Nkarta held its annual shareholder meeting on June 10, 2026.Investors backed an annual schedule for future advisory votes on executive pay; the board set the vote to occur every year.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. nkarta Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 11, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nNDL9XtZcY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4139","NKTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635808188","title":"Nkarta Insider Stock Sellers Must Be Relieved As Market Cap Falls To US$201m","url":"https://stock-news.laohu8.com/highlight/detail?id=2635808188","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635808188?lang=en_us&edition=fundamental","pubTime":"2026-05-15 19:13","pubTimestamp":1778843626,"startTime":"0","endTime":"0","summary":"Over the past year, insiders sold US$69k worth of Nkarta, Inc. ( NASDAQ:NKTX ) stock at an average price of US$2.06 per...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nktx/nkarta/news/nkarta-insider-stock-sellers-must-be-relieved-as-market-cap","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nktx/nkarta/news/nkarta-insider-stock-sellers-must-be-relieved-as-market-cap","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4505","BK4139","NKTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635736965","title":"Nkarta (NKTX) Gets a Buy from Stifel Nicolaus","url":"https://stock-news.laohu8.com/highlight/detail?id=2635736965","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635736965?lang=en_us&edition=fundamental","pubTime":"2026-05-13 23:15","pubTimestamp":1778685321,"startTime":"0","endTime":"0","summary":"Stifel Nicolaus analyst Stephen Willey maintained a Buy rating on Nkarta today and set a price target of $11.00. Willey covers the Healthcare secto...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/nkarta-nktx-gets-a-buy-from-stifel-nicolaus-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/nkarta-nktx-gets-a-buy-from-stifel-nicolaus-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4581","NKTX","BK4505","SF","XBI","BK4588","BK4585","BK4127","XLV","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635785293","title":"Nkarta Price Target Maintained With a $11.00/Share by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2635785293","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635785293?lang=en_us&edition=fundamental","pubTime":"2026-05-13 18:55","pubTimestamp":1778669700,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NKTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 13, 2026 06:55 ET (10:55 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635788051","title":"Nkarta Buy Rating Reaffirmed as NKX019 Autoimmune Trials Advance; $16 Price Target Maintained","url":"https://stock-news.laohu8.com/highlight/detail?id=2635788051","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635788051?lang=en_us&edition=fundamental","pubTime":"2026-05-13 18:19","pubTimestamp":1778667594,"startTime":"0","endTime":"0","summary":"Analyst Emily Bodnar of H.C. Wainwright maintained a Buy rating on Nkarta, retaining the price target of $16.00. Emily Bodnar has given his Buy rat...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/nkarta-buy-rating-reaffirmed-as-nkx019-autoimmune-trials-advance-16-price-target-maintained-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/nkarta-buy-rating-reaffirmed-as-nkx019-autoimmune-trials-advance-16-price-target-maintained-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NKTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635226535","title":"Nkarta reports Q1 EPS (37c), consensus (37c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635226535","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635226535?lang=en_us&edition=fundamental","pubTime":"2026-05-13 06:15","pubTimestamp":1778624115,"startTime":"0","endTime":"0","summary":"“Putting patients first and providing access to care in a familiar setting close to home matters” said Paul Hastings, CEO of Nkarta (NKTX). “In ear...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nkarta-reports-q1-eps-37c-consensus-37c-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nkarta-reports-q1-eps-37c-consensus-37c-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NKTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635240708","title":"Nkarta Q1 EPS $(0.37), Inline","url":"https://stock-news.laohu8.com/highlight/detail?id=2635240708","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635240708?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:33","pubTimestamp":1778618021,"startTime":"0","endTime":"0","summary":"Nkarta (NASDAQ:NKTX) reported quarterly losses of $(0.37) per share which met the analyst consensus estimate. This is a 13.95 percent increase over losses of $(0.43) per share from the same period last year.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52507720/nkarta-q1-eps-0-37-inline","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Nkarta Q1 EPS $(0.37), Inline","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635403842","title":"Nkarta Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2635403842","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635403842?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:17","pubTimestamp":1778617030,"startTime":"0","endTime":"0","summary":"Nkarta Inc reports results for the quarter ended March 31 - Earnings SummaryNkarta Inc NKTX.OQ reported a quarterly adjusted loss of 37 cents per share for the quarter ended March 31, higher than the ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nL8N41P31M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","NKTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635247245","title":"Nkarta Q1 net loss narrows; cash seen funding to 2029","url":"https://stock-news.laohu8.com/highlight/detail?id=2635247245","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635247245?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:11","pubTimestamp":1778616665,"startTime":"0","endTime":"0","summary":"Nkarta Q1 net loss narrows;cash seen funding to 2029OverviewUS biotechnology firm's Q1 net loss was $27.8 mln, basic EPS at -$0.37Cash and investments totaled $266.7 mln, expected to fund operations i","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nL1N41P1CI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4139","NKTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635242056","title":"Nkarta Q1 FY26 net loss narrows to $27.8 million; G&A expenses drop to $5.9 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635242056","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635242056?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:02","pubTimestamp":1778616162,"startTime":"0","endTime":"0","summary":"Nkarta posted a net loss of $27.8 million, or $0.37 per share, for Q1 2026.R&D expense edged up to $25 million, while G&A expense dropped to $5.9 million.Cash, cash equivalents, restricted cash, and investments fell to $266.7 million as of March 31, with runway expected to fund operations into 2029.Protocol changes agreed with FDA allow outpatient dosing in community settings, add an option to re-dose, remove overnight monitoring requirements, and expand Ntrust-2 to include rheumatoid arthritis.Enrollment continues at the 4 billion-cell dose level across Ntrust-1 and Ntrust-2, with initial clinical data planned for presentation at a medical meeting in 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL8GgHxb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","NKTX","LU2095319765.USD","IE00BN0W2T93.GBP","LU0314104364.USD","IE00BN0W2W23.USD","IE00BKPKM429.USD","IE00B3QW5Z07.USD","BK4505","SG9999014039.USD","SG9999014013.SGD","SG9999014005.SGD","BK4112","BK4139","LU2210150020.SGD","BK4585","BK4588","IE00BN0W2V16.EUR","SG9999014021.USD","NDAQ","IE00B64PRP62.GBP","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635242200","title":"BRIEF-Nkarta Q1 EPS USD -0.37","url":"https://stock-news.laohu8.com/highlight/detail?id=2635242200","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635242200?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:01","pubTimestamp":1778616105,"startTime":"0","endTime":"0","summary":"BRIEF-Nkarta Q1 EPS USD -0.37\n\n\nMay 12 (Reuters) - Nkarta Q1 net income USD -27.832 million.\n\nQ1 basic EPS USD -0.37\nQ1 cash & investments USD 266.7 million","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nPLXCE07AE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NKTX","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635422472","title":"Nkarta Q1 Cash & Investments USD 266.7 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635422472","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635422472?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:01","pubTimestamp":1778616060,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nPLXCE07AE:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4505","BK4139","NKTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635242065","title":"Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2635242065","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635242065?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:01","pubTimestamp":1778616060,"startTime":"0","endTime":"0","summary":"Enrollment ongoing at 4 billion cell dose level (12 billion cells in 3-dose cycle) across all indications in Ntrust-1 and Ntrust-2 Regulatory agreement supports expansion into community-based settings","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/12/3293350/0/en/Nkarta-Reports-First-Quarter-2026-Financial-Results-and-Corporate-Highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4230","BK4505","BK4022","NKTX","BK4139","CAR"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.nkartatx.com","stockEarnings":[{"period":"1week","weight":0.1943},{"period":"1month","weight":0.3466},{"period":"3month","weight":0.4632},{"period":"6month","weight":0.6019},{"period":"1year","weight":1},{"period":"ytd","weight":0.827}],"compareEarnings":[{"period":"1week","weight":0.0013},{"period":"1month","weight":0.0138},{"period":"3month","weight":0.1061},{"period":"6month","weight":0.0844},{"period":"1year","weight":0.2047},{"period":"ytd","weight":0.0965}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a lymphocyte that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, that is in phase I for the treatment of various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.051655},{"month":2,"riseRate":0.5,"avgChangeRate":0.038672},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.082697},{"month":4,"riseRate":0.666667,"avgChangeRate":0.177626},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.08485},{"month":6,"riseRate":0.166667,"avgChangeRate":-0.112595},{"month":7,"riseRate":1,"avgChangeRate":0.122337},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.06764},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.061634},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.060284},{"month":11,"riseRate":0.5,"avgChangeRate":-0.004483},{"month":12,"riseRate":0.333333,"avgChangeRate":0.310979}],"exchange":"NASDAQ","name":"Nkarta","nameEN":"Nkarta"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Nkarta(NKTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Nkarta(NKTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Nkarta,NKTX,Nkarta股票,Nkarta股票老虎,Nkarta股票老虎国际,Nkarta行情,Nkarta股票行情,Nkarta股价,Nkarta股市,Nkarta股票价格,Nkarta股票交易,Nkarta股票购买,Nkarta股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Nkarta(NKTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Nkarta(NKTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction